Radiation and drug therapy for stage IVB cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests combining external and internal radiation with chemotherapy and immunotherapy for stage IVB cervical cancer that has not been treated before. The goal is to see if this approach can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old with stage IVB cervical cancer (a type that has spread beyond the cervix).
- Your cancer must be a specific type (squamous cell, adenocarcinoma, or adenosquamous) and not have been treated with chemotherapy or radiation yet.
- You need to have a tumor sample (from a biopsy or previous surgery) available for testing, and your PD-L1 score must be above 1.
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1) and have adequate blood counts and organ function.
- You cannot have had certain prior treatments like immunotherapy targeting PD-1/PD-L1, a hysterectomy, or radiation for cervical cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for cervical cancer that has come back or spread after standard therapy. It combines an immunotherapy drug (AK104) with a type of internal radiation (I-125 brachytherapy) to see if it can shrink tumors and help patients live longer.
This trial tests a shorter course of radiation combined with chemotherapy and brachytherapy (internal radiation) for cervical cancer that has not spread widely. It aims to make treatment more efficient while still being effective.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This trial tests a new combination treatment for cervical cancer that has come back or spread. It may be an option for people who have not had previous systemic therapy for this stage of cancer.
This trial tests a drug called adebrelimab combined with standard chemotherapy and radiation for cervical cancer. It may be an option for people with stage IIB to IVA cervical cancer who have not had prior treatment.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
Hear when a new Cervical Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.